Preclinical Efficacy Data of Apogenix’ HERA-CD40L Published in Journal of Immunotherapy
HERA-CD40L Induces T-Cell-Mediated Anti-Tumor Immune Response through Activation of Antigen-Presenting Cells
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in Journal of Immunotherapy1 demonstrate the potent anti-tumor efficacy of Apogenix’ HERA-CD40L. HERA-CD40L acts directly on cells of the innate immune system as well as on antigen-presenting cells, thereby promoting specific T cell-mediated anti-tumor immunity. In contrast to antibodies, HERA-CD40L does not depend on Fcγ receptor-mediated crosslinking for activity. As the first pure CD40 receptor agonist with a well-defined mechanism of action, HERA-CD40L is not restrained by dose-limiting toxicities observed with anti-CD40 antibodies.